ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "juvenile idiopathic arthritis (JIA)"

  • Abstract Number: 3245 • 2015 ACR/ARHP Annual Meeting

    Factors Associated with Physical Activity in Older Children with Juvenile Idiopathic Arthritis

    Jennifer R. Horonjeff1, Shira Weiner2, Susan Klepper3, Ali Sheikhzadeh2, Philip Kahn4 and Sherri Weiser2, 1Ergonomics and Biomechanics, New York University, New York, NY, 2Orthopedics, New York University, New York, NY, 3Physical Therapy Program, Columbia University, New York, NY, 4Pediatric Rheumatology, New York University, New York, NY

    Background/Purpose: The purpose of this study was to examine factors associated with physical activity (PA) in children with JIA.  PA is important for the physical,…
  • Abstract Number: 1475 • 2015 ACR/ARHP Annual Meeting

    Fatigue, Quality of SLEEP and PAIN in Children with Juvenile Idiopathic Arthritis

    Ela Tarakci1, Saime Nilay Baydogan2, Kenan Barut3 and Ozgur Kasapcopur4, 1Division of Physiotherapy and Rehabilitation, Faculty of Health Science, Istanbul University,, Associate Professor, Istanbul, Turkey, 2Division of Physiotherapy and Rehabilitation, Faculty of Health Science, Istanbul University,, Assistant Professor, Istanbul, Turkey, 3Pediatric Rheumatology, Istanbul University, Cerrahpasa Medical Faculty, Istanbul, Turkey, 4Istanbul University, Cerrahpasa Medical School, Department of Pediatric Rheumatology, Professor of Pediatric Rheumatology, Istanbul, Turkey

    Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is one of the most common rheumatic diseases in childhood, affecting at least 1 in 1000 children (1). Children with…
  • Abstract Number: 1479 • 2015 ACR/ARHP Annual Meeting

    Qualitative Assessment of Patient Important Long-Term Outcomes in Juvenile Idiopathic Arthritis

    Melissa L. Mannion1, Michelle Williams2, Nataliya Ivankova3, Gerald McGwin Jr.4, Kenneth G. Saag5 and Timothy Beukelman6, 1Pediatrics, University of Alabama at Birmingham, Birmingham, AL, 2School of Public Health, University of Alabama at Birmingham, Birmingham, AL, 3Health Services Administration, University of Alabama at Birmingham, Birmingham, AL, 4Epidemiology, University of Alabama at Birmingham, Birmingham, AL, 5University of Alabama at Birmingham, Birmingham, AL, 6Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: The aim of this study was to identify and characterize the factors that JIA patients in young adulthood use to define a successful disease…
  • Abstract Number: 1482 • 2015 ACR/ARHP Annual Meeting

    Temporomandibular Pain in Patients with Juvenile Idiopathic Arthritis

    Peter Stoustrup1, Marinka Twilt2, Bernd Koos3, N Tzaribachev4, Troels Herlin5, Thomas Klit Pedersen6 and Lynn R. Spiegel7, 1Section of Orthodontics, University of Aarhus, Aarhus C, Denmark, 2Pediatric Rheumatology, Aarhus University Hospital, Aarhus, Denmark, 3Orthodontics, University of Rostock, Rostock, Germany, 4Pediatric Rheumatology, PRI - Pediatric Rheumatology Research Institute, Bad Bramstedt, Germany, 5Pediatric Rheumatology Clinic, Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark, 6orthodontics, Aarhus University Hospital/Dental school, Aarhus, Denmark, 7Rheumatology/Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada

    Background/Purpose: Joint pain is a primary symptom in Juvenile Idiopathic Arthritis (JIA). Experience of pain has been shown to be a significant predictor of impaired…
  • Abstract Number: 2026 • 2015 ACR/ARHP Annual Meeting

    A Novel Technique for Quantifying Synovial Enhancement of Temporomandibular Joints from Mris of Patients with Juvenile Idiopathic Arthritis

    Cory M. Resnick1, Pouya Vakilian2, Micheal Breen3, David Zurakowski4, Zachary S. Peacock5 and Leonard B. Kaban5, 1Plastics and Oral Surgery, Boston Children's Hospital, boston, MA, 2Harvard School of Dental Medicine, Boston, MA, 3Radiology, Boston Children's Hospital, Boston, MA, 4Departments of Anesthesia and Surgery, Boston Children’s Hospital, Boston, MA, 5Oral and Maxillofacial Surgery, Massachusetts General Hospital, Boston, MA

    Background/Purpose: Juvenile Idiopathic Arthritis (JIA) commonly affects the temporomandibular joints (TMJ) and may cause growth disturbance, functional limitation and facial deformity. Early diagnosis and management…
  • Abstract Number: 2171 • 2015 ACR/ARHP Annual Meeting

    A Comparison of Maternal Outcomes in Women with and without Juvenile Idiopathic Arthritis

    Debbie Ehrmann Feldman1, Sasha Bernatsky2, Evelyne Vinet3, Ciarán M. Duffy4, Elizabeth Hazel5, Garbis Meshefedjian6, Marie-Pierre Sylvestre7 and Anick Bérard1, 1Université de Montréal, Montréal, QC, Canada, 2Rheum/Clin. Epid., McGill MUHC/RVH, Montreal, QC, Canada, 3McGill University Health Centre, Montreal, QC, Canada, 4Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada, 5Rhematology, McGill University Health Centre, Montreal, QC, Canada, 6Public Health Department of Montreal, Montreal, QC, Canada, 7Université de Montréal, Montreal, QC, Canada

    Background/Purpose: Although there is a higher frequency of adverse maternal outcomes in mother with rheumatoid arthritis, little is known regarding mothers with juvenile idiopathic arthritis…
  • Abstract Number: 2416 • 2015 ACR/ARHP Annual Meeting

    Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Pediatric Patients from Six to Less Than Eighteen Years of Age with Juvenile Idiopathic Arthritis

    Hermine I. Brunner1, Nicolino Ruperto2, Nikolay Tzaribachev3, Zbigniew Zuber4, Elena Koskova5, Ivan Foeldvari6, Eizbieta Smolewska7, Gerd Horneff8, Charles Mebus9, Umberto Conte10, Rong Wang9, Christine Alvey9, Manisha Lamba9, Anasuya Hazra11, Daniel Lovell12 and Alberto Martini13, 1Pediatric Rheumatology Collaborative Study Group, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Istituto G. Gaslini, Pediatria II, PRINTO, Genoa, Italy, 3Pediatric Rheumatology, Bad Bramstedt, Germany, 4St Louis Children’s Hospital ODS Rheumatology and Neurology, Krakow, Poland, 5Institute of Rheumatic Diseases, Piestany, Slovakia, 6Hamburger Zentrum für Kinder-und Jugendrheumatologie, Hamburg, Germany, 7Department of Pediatric Cardiology and Rheumatology, Medical University of Lodz, Lodz, Poland, 8Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Germany, 9Pfizer Inc, Groton, CT, 10Pfizer Inc, New York, NY, 11Pfizer Inc, Collegeville, PA, 12Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 13Istituto G. Gaslini, Pediatria II, PRINTO, and University of Genoa, Genoa, Italy

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of adult patients with rheumatoid arthritis (RA). We report the pharmacokinetics (PK), safety and…
  • Abstract Number: 2423 • 2015 ACR/ARHP Annual Meeting

    An Open-Label Extension Study to Assess the Long-Term Safety and Clinical Benefit of Etanercept on Children and Adolescents with Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, or Psoriatic Arthritis: A 4-Year Update

    Nicolino Ruperto1, Tamas Constantin2, Ivan Foeldvari3, Jelena Vojinovic4, Gerd Horneff5, Rubén Burgos-Vargas6, Irina Nikishina7, Jonathan Akikusa8, Tadej Avcin9, Jeffrey Chaitow10, Elena Koskova11, Bernard R. Lauwerys12, Inmaculada Calvo-Penedes13, Berit Flato14, Maria Luz Gamir Gamir15, Hans-Iko Huppertz16, Juan Jose Jaller Raad17, Katerina Jarosova18, Jordi Anton19, Marie Macku20, William Jose Otero Escalante21, Lidia Rutkowska-Sak22, Ralf Trauzeddel23, Carine Wouters24, Ronald Pedersen25, Sameer Kotak26, Jack F Bukowski27, Tina Hinnershitz28, Bonnie Vlahos29 and Alberto Martini30, 1Pediatria II, PRINTO, Istituto G. Gaslini, Universita' di Genova, Genova, Italy, 2Semmelweis University, Budapest, Hungary, 3Hamburg Centre for Child and Adolescent Rheumatology, Hamburg, Germany, 4Faculty of Medicine, University of Nis, Nis, Serbia, 5Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, 6Rheumatology, Hospital General de Mexico, Mexico city, Mexico, 7V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, 8Rheumatology, Royal Children's Hospital, Melbourne, Australia, 9Allergology, Rheumatology and Clinical Immunology, University Medical Center Ljubljana, Ljubljana, Slovenia, 10The Sydney Children's Hospital Network, Sydney, Australia, 11National Institute of Rheumatic Diseases, Piestany, Slovakia, 12Cliniques Universitaires Saint-Luc, Brussels, Belgium, 13Hospital Universitario y Piltecnico La Fe, Valencia, Spain, 14Oslo University Hospital, Oslo, Norway, 15Rheumatology, Hospital Ramon y Cajal Unidad de Reumatologia Pediatrica, Madrid, Spain, 16Klinikum Bremen-Mitte, Prof.-Hess-Kinderklinik, Bremen, Germany, 17Centro de Reumatologia y Ortopedia, Barranquilla, Colombia, 18Revmatologicky ustav, Prague, Czech Republic, 19Unitat de Reumatologia Pediàtrica, Hospital Sant Joan de Déu, Barcelona, Spain, 201, Facutly Children's Hospital Brno, Brno, Czech Republic, 21Servimed S.A.S, Santander, Colombia, 22Instytut Reumatologii, Klinika i Poliklinika Reumatologii Wieku Rozwojowego, Warszawa, Poland, 23HELIOS Klinikum Berlin-Buch Klinik fuer Kinder- und Jugendmedizin, Berlin, Germany, 24UZ Leuven, Leuven, Belgium, 25Department of Biostatistics, Pfizer, Collegeville, PA, 26Global Health and Value, Pfizer, New York, NY, 27Pfizer, Collegeville, PA, 28Specialty Care MDG, Pfizer, Collegeville, PA, 29GIPB - Clinical Sciences, Pfizer, Collegeville, PA, 30Istituto G. Gaslini, Universita' di Genova, Genova, Italy

    Background/Purpose: A Phase 3b, open-label, multicenter study (CLIPPER; NCT00962741) demonstrated the efficacy of etanercept (ETN) in subjects with the extended oligoarticular (eo), enthesitis-related (ERA), and…
  • Abstract Number: 2432 • 2015 ACR/ARHP Annual Meeting

    The Preventive Effect of Methotrexate on Uveitis Onset in JIA Depends on Uveitis Risk Factors

    Mikhail Kostik1, Ekaterina Gaidar1, Margarita Dubko1, Ludmila Snegireva2, Vera Masalova2, Irina Chikova1, Eugenia Isupova3, Tatiana Nikitina4, Elena Serogodskaya1, Olga Kalashnikova1, Angelo Ravelli5 and Vyacheslav Chasnyk3, 1State Pediatric Medical University, Saint-Petersburg, Russia, 2Hospital Pediatrics, State Pediatric Medical University, Saint-Petersburg, Russia, 3Hospital Pediatry, State Pediatric Medical University, Saint-Petersburg, Russia, 4State Pediatric Medical University, St. Petersburg, Russia, 5Pediatria-II, IRCCS G. Gaslini and University of Genova, Genova, Italy

    Background/Purpose: Uveitis is the most common extra-articular manifestation of juvenile idiopathic arthritis (JIA), often entirely asymptomatic but could be sight-threatening. The main predictors of uveitis…
  • Abstract Number: 2437 • 2015 ACR/ARHP Annual Meeting

    Experience with Tocilizumab for Treatment of 56 Children with Systemic Juvenile Idiopathic Arthritis in the German JIA Biologics Register

    Gerd Horneff1, Gerd Ganser2, Johannes Peter Haas3, Toni Hospach4, Ralf Trauzeddel5, Hans-Iko Huppertz6, J B. Kuemmerle-Deschner7, Kirsten Minden8 and BIKER Registry Study Group, 1Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, 2Pediatric Rheumatology, Sankt Josef Stift, Sendenhorst, Germany, 3German Centre for Rheumatology in Children and Young People, Garmisch-Partenkirchen, Germany, 4Pediatrics, Olgahospital, Klinikum Stuttgart, Stuttgard, Germany, 5HELIOS Klinikum Berlin-Buch Klinik fuer Kinder- und Jugendmedizin, Berlin, Germany, 6PRINTO, IRCCS G. Gaslini, Genoa, Italy, 7Pediatrics, University Hospital Tuebingen, Tuebingen, Germany, 8DRFG, Berlin, Germany

    Background/Purpose: Tocilizumab (TOC) has become a valuable option for treatment of systemic juvenile idiopathic arthritis (sJIA), which significantly improved the outcome of patients. The aim…
  • Abstract Number: 930 • 2015 ACR/ARHP Annual Meeting

    Evaluation of Temporomandibular Joint Arthritis with Ultrasound in Juvenile Idiopathic Arthritis

    Edward J. Oberle1,2, James Nocton3 and Arthur Meyers4, 1Pediatrics, Ohio State University, Columbus, OH, 2Pediatric Rheumatology, Nationwide Children's Hospital, Columbus, OH, 3Pediatrics, Medical College of Wisconsin, Milwaukee, WI, 4Radiology, Children's Hospital of Wisconsin, Milwaukee, WI

    Background/Purpose: Temporomandibular joint (TMJ) arthritis is a common yet widely under recognized feature of Juvenile Idiopathic Arthritis (JIA).  It is often clinically silent and difficult…
  • Abstract Number: 2444 • 2015 ACR/ARHP Annual Meeting

    Accelerometer-Assessed Daily Physical Activity in Relation to Pain Cognitions and Quality of Life in Juvenile Idiopathic Arthritis

    Mette Noergaard1, Johanne Lomholt2, Mikael Thastum2, Morten Herlin3, Marinka Twilt4 and Troels Herlin4, 1Department of Physiotherapy, Aarhus University Hospital, Aarhus, Denmark, 2Psychology and Social Sciences, Aarhus University, Aarhus, Denmark, 3Pediatrics, Aarhus University Hospital, Aarhus, Denmark, 4Pediatric Rheumatology Clinic, Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark

    Background/Purpose: Juvenile Idiopathic Arthritis (JIA) has been associated with decreased physical activity (PA). However, accurate, objective measurements of PA related to potential factors limiting PA…
  • Abstract Number: 957 • 2015 ACR/ARHP Annual Meeting

    Double Blind Placebo Controlled Randomized Trial of Probiotics in Enthesitis-Related-Arthritis Category of JIA: Effect on Clinical and Immunological Parameters

    Anuj Shukla1, Priyanka Gaur2 and Amita Aggarwal1, 1Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, 2Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India

    Background/Purpose: Gut microflora influences the development and homeostasis of the immune system. Dysbiosis has been reported in various immuno-inflammatory diseases. Pathogenesis of enthesitis-related-arthritis (ERA) category…
  • Abstract Number: 2445 • 2015 ACR/ARHP Annual Meeting

    Development and Usability Testing of an Ipad-Based Psycho-Educational Game for Children with Juvenile Idiopathic Arthritis and Their Parents

    Jennifer N. Stinson1, Adam M. Huber2, Mark Connelly3, Nadia Luca4, Lynn R. Spiegel5, Argerie Tsimicalis6, Stephanie Luca7, Roberta Berard8, Julie Barsalou9, Sarah Campillo10, Paul Dancey11, Ciarán M. Duffy12, Brian Feldman13, Nicole Johnson4, Patrick McGrath14, Natalie J. Shiff15, Shirley M Tse16, Lori B. Tucker17 and J. Charles Victor18, 1Anesthesia and Pain Medicine, The Hospital for Sick Children, Toronto, ON, Canada, 2Pediatric rheumatology, IWK Health Centre, Halifax, NS, Canada, 3Psychology, University of Kansas Medical Center, Kansas City, KS, 4Pediatrics/Alberta Children's Hospital, Department of Pediatrics/University of Calgary, Calgary, AB, Canada, 5Rheumatology/Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada, 6McGill University, Montreal, QC, Canada, 7The Hospital for Sick Children, Toronto, ON, Canada, 8Children's Hospital of Western Ontario, London, ON, Canada, 9CHU Sainte-Justine, Université de Montréal, Montreal, QC, Canada, 10Rheumatology, Montreal Children's Hospital, Montreal, QC, Canada, 11Health Science Centre, Memorial University of Newfoundland, St Johns, NF, Canada, 12Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada, 13Division of Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, 14IWK Health Centre, Halifax, NS, Canada, 15Pediatric Rheumatology, University of Saskatchewan, Saskatoon, SK, Canada, 16Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, 17Rheumatology, BC Children's Hospital, Vancouver, BC, Canada, 18University of Toronto, Toronto, ON, Canada

    Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is a common chronic childhood illness that can negatively impact health-related quality of life (HRQL). In younger years, children manage…
  • Abstract Number: 302 • 2014 ACR/ARHP Annual Meeting

    Qualitative Assessment of Important Long-Term Outcomes in Juvenile Idiopathic Arthritis

    Melissa L. Mannion1, Michelle Williams2, Gerald McGwin Jr.3, Kenneth G. Saag4 and Timothy Beukelman1, 1Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 2School of Public Health, University of Alabama at Birmingham, Birmingham, AL, 3Epidemiology, University of Alabama at Birmingham, Birmingham, AL, 4Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose JIA is not a childhood disease, but a chronic disease that begins in childhood. Long term outcomes that physicians and patients care most about…
  • « Previous Page
  • 1
  • …
  • 12
  • 13
  • 14
  • 15
  • 16
  • …
  • 19
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology